Mithra Pharmaceuticals: MITHRA LAUNCHES ITS PRODUCT TIBELIA

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Mithra Pharmaceuticals: MITHRA LAUNCHES ITS PRODUCT TIBELIA ON THE GLOBAL MARKET

                                                                                                                                                         PRESS RELEASE

Mithra launches ITS product Tibelia [1] on the GLOBAL market

  • Mithra Pharmaceuticals received 14 Marketing Authorizations (MA) in 12 European countries for its product based on tibolone.
  • Mithra should receive shortly 3 more authorizations for France, Italy and Greece.
  • Tibelia received 24 months' shelf-life and should be able to extend this to 36 months in 2017, what would give the product a unique advantage on the market and would make it more competitive than its competitors.
  • In 2016, Mithra signed 8 License and Supply Agreements.
  • Mithra expects to sign other agreements with Ukraine, Russia, Chile, Singapore, France and Switzerland.
  • Mithra estimates, according to the sales forecasts of his distributors, incomes in double digit for the next five years.

Liège, Belgium, 22 December 2016 - Mithra Pharmaceuticals, a company focused on Women's Health, announces today that it obtained 14 Marketing Authorizations for the commercialization of its product Tibelia in the United Kingdom, Belgium, Holland, Luxembourg, Spain, Portugal, Germany, Hungary, Poland, Norway, Sweden and Finland. Mithra is still waiting for 3 MA in France, Greece and Italy that should be received by the beginning of 2017.

The product based on tibolone developed by Mithra will be more competitive due to its extended shelf-life.

Valérie Gordenne, CSO Mithra Pharmaceuticals: " At this stage, we believe we can justify a shelf-life of 36 months versus 24 months for the competitors. Currently, data are available on 24 months for the pilot batches. Trends show a possible stability extension. The results are confirmed on the first industrial batch (18 months). The best stability of the active ingredient in the formulation is linked to specific components of this formulation, for which a patent has been applied."

In 2016, Mithra signed 8 License and Supply Agreements in the United Kingdom, Spain, Switzerland, Germany, Benelux, Australia, South Africa, Canada and Finland for a total amount in double digit, down payments included. In 2017, Mithra expects to sign other agreements with Ukraine, Russia, Chile, Singapore and France

In United Kingdom, marketing is already effective, as well as it will be effective in Spain and Holland in January 2017.

François Fornieri CEO Mithra Pharmaceuticals: "Obtaining a Marketing Authorization for a product candidate is a real recognition of the unique expertise of our team in terms of development and regulatory affairs. Tibelia is set to be a competitor on the European market. It is indeed a 'complex' therapeutical solution as tibolone, the active ingredient involved, is known as a particularly unstable active ingredient, presenting many challenges in terms of development. Obtaining marketing authorisations for such a product is a significant validation for Mithra's development and regulatory expertise, which was previously demonstrated in the development of Mithra's first R&D projects developed in the past, and which will continue to serve it well as it continues to develop and prepare the regulatory pathway for its lead products based on Estetrol."

The global market of tibolone is an attractive and growing market of EUR 131 million [2] , accounting for an increase of 4.3% in value [3] . In terms of volume, this market represents 315 million tablets, up 2% [4] . 

About Tibelia

Tibelia is a synthetic steroid (tibolone) intended to be used for hormone replacement therapy. Tibelia is a product that mimics the activity of the female sex hormones in the body, and is used especially for the relief of symptoms occurring after menopause. In some countries, this product is also used for the prevention of osteoporosis. It has been demonstrated that tibolone has favourable effects on various tissues in the body, such as brain, vagina and bone [5] .

Pictures

For pictures of François Fornieri, please click on the following link:

http://www.mithra.com/en/logo/

For more information, please contact:

Press

Julie Dessart Chief Communication Officer +32 4 349 28 22 / +32 475 86 41 75 press@mithra.com

Investor Relations

François Fornieri, CEO +32 4 349 28 22 investorrelations@mithra.com

Consilium Strategic Communications Jonathan Birt, Sue Stuart, Hendrik Thys +44 2 037 095 700 mithra@consilium-comms.com

About Mithra

Mithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart, is a Euronext listed pharmaceutical company (MITRA) focused on Women's Health. Mithra's mission is to improve every stage of women's life with innovative and accessible pharmaceutical solutions. As such the Company aims to become a worldwide leader in women's health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and complex therapeutical solutions in four therapeutic fields of women's health: fertility and contraception, menopause and osteoporosis, gynecological infections and female cancers.

Mithra has an approximate headcount of 141 staff members and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To subscribe to Mithra's newsletter, visit investors.mithra.com

[1] Code name for the product based on Tibolone developed by Mithra. Every distributor is free to choose the name he wishes to commercialize locally.

[2] Source : IMS Q3/2015

[3] Source : IMS Q3/2015

[4] Source : IMS Q3/2015

[5] Livial ® Patient Information Leaflet.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TORM Rejects Hafnia's No-Premium Merger Pitch Again

Updated Category News Views 112

A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...

Continue Reading
ETCO Targets the Unflashy Weak Link in Battery Storage

Updated Category News Views 38

A battery cabinet can look impressive right up until one lousy connection becomes the problem nobody budgeted for. ETCO Incorporated’s new lineup of standard and custom connectors and terminals goes after that unglamorous part of battery energy storage systems: the physical handoff points carrying power, grounding equipment, and tying auxiliary components together. It...

Continue Reading
Epsium's Inventory Pile Looms Over Weak First Half

Updated Category News Views 73

A warehouse full of bottles is not a balance-sheet fortress when buyers are backing away. Epsium Enterprise’s first-half 2026 report is a rough read: revenue collapsed 51.8% to $1.47 million, gross profit fell to $175,353, and cash slid to $612,761 at June 30. This is not a subtle slowdown. Macau’s premium Chinese-liquor market has been weak on both demand and...

Continue Reading
Pacific Surfliner Faces Thanksgiving Capacity Test

Updated Category News Views 76

Thanksgiving traffic on Southern California freeways is its own yearly punishment, and the Pacific Surfliner is making a sensible pitch: leave the car parked and let the coast roll past the window. For travelers, that can be a real relief. For anyone watching public transportation, this is also a useful little stress test of whether a busy state-supported rail corridor...

Continue Reading
Knowles Expands Its Teacher Pipeline With 39 Fellows

Updated Category News Views 79

Thirty-Nine Teachers Is Not a Trivial Signal Thirty-nine new math and science teachers may not rattle public markets, but it says plenty about where the real strain sits in American education. The Knowles Teacher Initiative has named its 2026 Teaching Fellowship class, its largest ever, and the timing is dead serious: schools are still wrestling with recruiting and...

Continue Reading
Rokt's 164% Growth Shows Checkout Ads Have Real Muscle

Updated Category News Views 146

Checkout screens have become valuable real estate, and Rokt is planting a flag right in the middle of them. The New York ecommerce technology company landed on Deloitte's 2026 Technology Fast 500 after posting 164% revenue growth from 2022 through 2025. That is a meaningful number, not decorative corporate confetti, especially in a digital-ad market where plenty of...

Continue Reading
PARRIS Partners Earn 2026 Plaintiff Lawyer Recognition

Updated Category News Views 49

A $58.4 million jury number can make a courtroom sound like a slot machine, until the final settlement lands at $21 million. That gap is the part people ought to stare at before getting carried away by another plaintiff-lawyer honor roll. The Daily Journal has named PARRIS Law Firm partners Alexander R. Wheeler and Khail A. Parris to its 2026 Top Plaintiff Lawyers special...

Continue Reading
Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 165

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 171

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 138

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading

Top 5 Most Recently Viewed Articles

Artisan Partners Asset Management's Q2 Performance and Highlights

Updated Category News Views 124

Artisan Partners Asset Management Inc. Reports Strong Q2 Performance Artisan Partners Asset Management Inc. (NYSE: APAM) recently showcased its financial success for the quarter ending June 30, 2025. The Company, renowned for its investment strategies, declared a quarterly dividend as part of its results presentation. This reflects Artisan's commitment to providing value...

Continue Reading
LVMH Reports Recent Share Transactions and Market Activity

Updated Category News Views 240

Understanding LVMH's Share Transactions Recently, LVMH Moët Hennessy Louis Vuitton disclosed share transactions conducted between exciting dates. This information was provided to the regulatory body, ensuring transparency for investors and industry stakeholders alike. As one of the leading companies in the luxury goods sector, LVMH’s transactions are always...

Continue Reading
Dynavax Technologies to Share Insights at Healthcare Conference

Updated Category News Views 160

Dynavax's Upcoming Participation in Healthcare Conference Dynavax Technologies Corporation (Nasdaq: DVAX), a prominent player in the biopharmaceutical landscape, is set to take part in a pivotal fireside chat at the 8th Annual Evercore Healthcare Conference. This insightful event will take place on an upcoming Tuesday at 2:10 p.m. ET. Investors and healthcare stakeholders...

Continue Reading
Growing Demand for 3D Surveillance Cameras by 2030

Updated Category News Views 301

The Growing Market for 3D Surveillance Cameras The global 3D surveillance camera market is on the brink of substantial growth, with forecasts indicating it could reach an impressive $7.92 billion by 2030. This surge is primarily fueled by increased investments in defense and public safety initiatives around the world. A key factor in this trend is the rising use of 3D...

Continue Reading
LVMH Stock Upgrade by BofA Signals Strong Growth Ahead

Updated Category News Views 317

LVMH Receives Positive Rating Upgrade from Bank of America Recently, Bank of America made headlines by upgrading LVMH shares to a Buy rating, moving it from a previous Neutral stance. This upgrade places the renowned luxury goods giant on its prestigious Europe 1 list of preferred investment ideas. Revised Price Targets Indicate Strong Potential The ratings agency has...

Continue Reading